Paper40964483
State of the art in treatment of small cell lung cancer.
Behrouzi R and 1 other. Ther Adv Med Oncol, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. State of the art in treatment of small cell lung cancer. Papers, record 40964483. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40964483
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References159
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18786981 | Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. | Thorax | 2009 | https://conductscience.org/library/papers/18786981 | PubMed |
| 2 | 34335926 | Genomic Profiling of Circulating Tumor DNA from Patients with Extensive-Stage Small Cell Lung Cancer Identifies Potentially Actionable Alterations. | J Cancer | 2021 | https://conductscience.org/library/papers/34335926 | PubMed |
| 3 | 24882383 | Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. | Lung Cancer | 2014 | https://conductscience.org/library/papers/24882383 | PubMed |
| 4 | 33439693 | Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33439693 | PubMed |
| 5 | 33864941 | Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. | Ann Oncol | 2021 | https://conductscience.org/library/papers/33864941 | PubMed |
| 6 | 37146473 | Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study. | Lung Cancer | 2023 | https://conductscience.org/library/papers/37146473 | PubMed |
| 7 | 39268857 | Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. | N Engl J Med | 2024 | https://conductscience.org/library/papers/39268857 | PubMed |
| 8 | 10441603 | Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10441603 | PubMed |
| 9 | 35279527 | Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. | ESMO Open | 2022 | https://conductscience.org/library/papers/35279527 | PubMed |
| 10 | 37037178 | Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy. | Lung Cancer | 2023 | https://conductscience.org/library/papers/37037178 | PubMed |
| 11 | 39541202 | Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial. | JAMA Oncol | 2025 | https://conductscience.org/library/papers/39541202 | PubMed |
| 12 | 28642008 | Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28642008 | PubMed |
| 13 | 30523756 | Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30523756 | PubMed |
| 14 | 30217489 | A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics. | J Thorac Oncol | 2019 | https://conductscience.org/library/papers/30217489 | PubMed |
| 15 | 38366589 | Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. | Cancer Cell | 2024 | https://conductscience.org/library/papers/38366589 | PubMed |
| 16 | 37027065 | A meta-analysis of circulating tumor DNA as a survival indicator in small cell lung cancer patients. | Clin Exp Med | 2023 | https://conductscience.org/library/papers/37027065 | PubMed |
| 17 | 35576956 | Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/35576956 | PubMed |
| 18 | 22473169 | Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22473169 | PubMed |
| 19 | 11008007 | A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. | Lung Cancer | 2000 | https://conductscience.org/library/papers/11008007 | PubMed |
| 20 | 37981084 | Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: A systematic review and meta-analysis. | Radiother Oncol | 2024 | https://conductscience.org/library/papers/37981084 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42882853 | AI-Driven Multi-Omics Approaches for Deciphering Small-Cell Lung Cancer Heterogeneity Using Nucleic-Acid-Based Features. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882853 | PubMed |
| 42813501 | From Real World Data to Real Impact: A Co-Medication Framework for Lung Cancer to Advance DDI Assessment and Patient-Centric Drug Development. | Clin Transl Sci | 2026 | https://conductscience.org/library/papers/42813501 | PubMed |
| 42649862 | Small Cell Lung Cancer in Transition: Recent Advances in Biology, Treatment, and Precision Medicine. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649862 | PubMed |
| 42582332 | DLL3-directed immune redirection in small-cell lung cancer: a lineage-defined vulnerability that doubles as an escape route. | Front Immunol | 2026 | https://conductscience.org/library/papers/42582332 | PubMed |
| 42558713 | Efficacy and safety of immunotherapy combined with chemoradiotherapy in limited-stage small cell lung cancer: a systematic evaluation and meta-analysis of randomized controlled trials. | Front Immunol | 2026 | https://conductscience.org/library/papers/42558713 | PubMed |
| 42088497 | The application and challenges of immune checkpoint inhibitors in lung cancer therapy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42088497 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40964483
GET https://conductscience.org/api/papers/v1/40964483/references?page=2